Veru (NASDAQ:VERU) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Veru (NASDAQ:VERU) announced its quarterly earnings data on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%.

Veru Trading Down 7.6 %

Shares of VERU traded down $0.04 during mid-day trading on Thursday, hitting $0.51. 2,887,448 shares of the company’s stock were exchanged, compared to its average volume of 5,203,067. The firm has a market capitalization of $74.36 million, a P/E ratio of -1.81 and a beta of -0.54. Veru has a fifty-two week low of $0.37 and a fifty-two week high of $1.92. The business’s 50 day moving average is $0.72 and its two-hundred day moving average is $0.77.

Analyst Upgrades and Downgrades

VERU has been the subject of several analyst reports. Oppenheimer reiterated an “outperform” rating and issued a $5.00 price objective on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Veru in a research report on Thursday, January 2nd.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.